World Kidney Day is a great opportunity to share promising findings. A collaborative study by Gnosis by Lesaffre and Omicron Pharmaceuticals indicated that Vitamin K2 supplementation with MenaQ7® may alleviate symptoms in individuals with severe calciphylaxis, a condition associated with poor kidney function.
Collaboration on a Case Study
Gnosis by Lesaffre, in partnership with Omicron Pharmaceuticals, has published a case study exploring the benefits of MenaQ7® Vitamin K2 as MK-7 supplementation for an individual with calciphylaxis, a condition related to poor kidney function. The study – “Exploring Novel Therapeutic Strategies for Calciphylaxis: A Focus on Vitamin K2 Supplementation” – was published in the Annals of Urology & Nephrology.
The Importance of Vitamin K2 for Kidney Health
Vitamin K deficiency is a significant risk factor for overall and cardiovascular mortality in individuals with kidney conditions. The vitamin K-dependent protein, Matrix Gla Protein (MGP), is known to inhibit calcification when activated. Previous research has shown that in those on dialysis, a slight decrease in active MGP significantly increased the risk of calciphylaxis, suggesting an association between K deficiency and the condition.
Promising Results in Calciphylaxis Management
In a recent case study, an individual experiencing severe symptoms of calciphylaxis reported significant improvements after supplementing with Vitamin K2 (MenaQ7®) at a dosage of 360 mcg per day. After one month of treatment, the individual noted that the pain had vanished, and the wounds began to heal, with complete healing achieved by the third month. The authors of the study suggest that Vitamin K2 supplementation may prove to be a promising therapy for managing calciphylaxis in patients undergoing dialysis. Ongoing research, such as the VIKIPEDIA study, is currently investigating the effects of higher dosages of MenaQ7® (1,000 mcg per day) to address potential deficiency levels.
Optimal Vitamin K2 Dosages for Kidney Health
Researchers are currently investigating the optimal dosage of K2 for kidney patients. Ongoing randomized controlled trials, such as the VIKIPEDIA study, are examining the effects of higher dosages of MenaQ7® (1,000 mcg/day) to address deficiency levels.